Thank you for your interest! This web site summarizes information on Immunic’s Phase 2 clinical trials in IBD, both in ulcerative colitis and Crohn’s disease. There is a public area with general information, with information on Immunic and the investigational drug IMU-838 and a pass-word protected area with information for medical professionals only. This web site is intended to give you more information so that you can judge your interest in participating in these trials.

Please feel free to get in touch with us via our contact page, if you require more information.

The mission of Immunic AG is to develop innovative immune modulators (in particular those that block TH17- and TH1-mediated immune and autoimmune responses) and bring these drug candidates to clinical proof of concept in patients.

Immunic has currently two ongoing development programs:

• IMU-838 (an inhibitor of DHODH) for development in IBD: Starting Phase 2
• IMU-366/935 (an inhibitor of RORγt) relevant to a range of disease: Preclinical

For further information, please also contact our web site: http://www.immunic-therapeutics.com/